Shares of Biocon Limited (NSE:BIOCON) last traded at 606.95, representing a move of 0.77%, or 4.65 per share, on volume of 2.31M shares. After opening the trading day at 600, shares of Biocon Limited traded in a close range. Biocon Limited currently has a total float of 590.99 million shares and on average sees 1.39 million shares exchange hands each day. The stock now has a 52-week low of 543.3 and high of 718.

The Success of India’s Equity Market

The potentials of the Asian economy cannot be undermined especially when they are driven by the success and prospects of thriving economies such as that of India.

The equity market is one of any nation’s gems. In India, the corporate sector represents roughly 14% of its gross domestic product (GDP). As a developing economy, this is already a compelling figure. In leading economies such as the US, the corporate sector represents 70% of national GDP.

Indian Equity Market

The Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) are the two main stock exchanges in the country. They represent about 4% of India’s GDP, with more than half of all publicly traded companies in the country listed on the BSE and the NSE.

BSE

The BSE, founded in 1875, is the oldest stock exchange not just in India but in Asia as well. It is the first entity to get a permanent recognition in India under the Securities Contract Regulation Act of 1956. Presently, it is the 11th biggest stock exchange globally with a total market capitalization of $1.70 trillion as of January 2015. With a speed of six microseconds, the BSE is also one of the fastest stock exchanges globally.

The SENSEX 30 is the index monitoring the top 30 stocks on the BSE based on various factors such as liquidity and market capitalization.

The BSE first attained a four-digit figure in July 1990. When the Bhartiya Janta Party won the General Elections in October 1999, it first attained the 5,000 mark. The BSE first attained the 10,000 mark in February 2006 and the 20,000 mark in December 2007. When the Global Financial Crisis of 2008 broke out, the BSE had posted its biggest losses, declining more than 2,000 points in just two consecutive trading days in January 2008. Biocon Limited is a stock traded on the Indian stock exchange.

Nonetheless, the BSE was able to recover from the turmoil. In March 2015, it first attained the 30,000 mark. Shortly after, it had once again posted one of its biggest one-day drop, losing 1,741 points in August 2015. The decline is primarily attributed to the devaluation of yuan. China is the biggest economy in Asia, which is why its economic downturn had a huge dent in the entire equity market of the region.

NSE

While the BSE is the first stock exchange in Asia, the NSE, founded in 1992, on the other hand, is the stock exchange that introduced electronic trading system in India. Because of its establishment, India had begun embracing and shifting to fully automated stock exchanges that are more efficient, reliable, and convenient. Biocon Limited has relatively good liquidity.

The NIFTY is the index monitoring the top 50 companies across more than 20 sectors on the NSE based on different factors, particularly market capitalization.

India is one of Asia’s leading economies. With its growth prospects and potentials, the growth opportunities seem limitless as well. Consequently, investing in the Indian stock market is highly advised nowadays, given the thriving success of both the BSE and NSE. Professional analysts might be interested how this will affect Biocon Limited.

More notable recent Biocon Limited (NSE:BIOCON) news were published by: Economictimes.Indiatimes.com which released: “We will get close to biosimilar guidance of $200 mn: Kiran Mazumdar Shaw, Biocon – Economic Times” on March 27, 2019, also Economictimes.Indiatimes.com with their article: “Share market update: Nifty Pharma index down; Biocon falls over 1% – Economic Times” published on March 13, 2019, Economictimes.Indiatimes.com published: “Share market update: Nifty Pharma index down; Biocon, Cipla among top losers – Economic Times” on March 22, 2019. More interesting news about Biocon Limited (NSE:BIOCON) were released by: Economictimes.Indiatimes.com and their article: “Share market update: Nifty Pharma index up; Biocon rises nearly 2% – Economic Times” published on February 28, 2019 as well as Economictimes.Indiatimes.com‘s news article titled: “Share market update: Nifty Pharma index flat; Dr. Reddy’s Lab down 1% – Economic Times” with publication date: March 28, 2019.

Biocon Limited, a biopharmaceutical company, develops, makes, and sells biopharmaceuticals for diabetes, cancer, and autoimmune conditions. The company has market cap of INR358.70 billion. The firm operates through Small Molecule APIs & Generic Formulations, Biologics, Branded Formulations, and Research Services divisions. It has a 43.99 P/E ratio. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, narrow spectrum antibiotics, and antifungals; and branded formulations in the areas of metabolics, oncology, immunology, and auto immune indications.